Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age.
Pleguezuelos P, Sibila M, Ramírez C, López-Jiménez R, Pérez D, Huerta E, Llorens AM, Pérez M, Correa-Fiz F, Mancera Gracia JC, Taylor LP, Smith J, Bandrick M, Borowski S, Saunders G, Segalés J, López-Soria S, Fort M, Balasch M.
Pleguezuelos P, et al. Among authors: borowski s.
Vaccines (Basel). 2022 Dec 9;10(12):2108. doi: 10.3390/vaccines10122108.
Vaccines (Basel). 2022.
PMID: 36560518
Free PMC article.